Efficacy and adverse effects of medications used in the treatment of glaucoma

Drugs and Aging

Volumn 15, Issue 5, 1999, Pages 377-388

  Camras, Carl B ^a   Toris, Carol B ^a   Tamesis, Richard R ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; ADRENALIN; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIGLAUCOMA AGENT; APRACLONIDINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BRIMONIDINE; BRINZOLAMIDE; CARBONATE DEHYDRATASE INHIBITOR; CLONIDINE; DIPIVEFRINE; DORZOLAMIDE; LATANOPROST; MIOTIC AGENT; PILOCARPINE; PROSTAGLANDIN DERIVATIVE; TIMOLOL;

ADJUVANT THERAPY; BURN; CLINICAL TRIAL; DRUG BINDING; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; EYE DISEASE; GLAUCOMA; GLAUCOMA SURGERY; HUMAN; HYPEREMIA; INFLAMMATION; INTRAOCULAR PRESSURE; INTRAVENOUS DRUG ADMINISTRATION; NEPHROLITHIASIS; ORAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RETINA MACULA EDEMA; REVIEW; TASTE DISORDER; TOPICAL DRUG ADMINISTRATION;

ADJUVANTS, PHARMACEUTIC; ADRENERGIC BETA-ANTAGONISTS; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; PROSTAGLANDINS; RANDOMIZED CONTROLLED TRIALS;

EID: 0032745199     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199915050-00005     Document Type: Review

References (82)

1. 1. Becker B. Decrease in intraocular pressure in man by a carbonic anhydrase inhibitor, diamox: a preliminary report. Am J Ophthalmol 1954; 37 (1): 13-5
2. 2. Zimmerman TJ, Kaufman HE. Timolol: dose response and duration of action. Arch Ophthalmol 1977; 95 (4): 605-7
3. 2-adrenergic agonists in the medical treatment of glaucoma. Curr Opin Ophthalmol 1994; 5 (2): 76-84
4. 4. Robin AL. Apraclonidine hydrochloride: its past, present, and future in the therapy of chronic glaucoma. J Glaucoma 1995; 4 Suppl. I: S214-9
5. 5. Robin AL, Ritch R, Shin DH, et al. Short-term efficacy of apraclonidine hydrochloride added to maximum-tolerated medical therapy for glaucoma. Am J Ophthalmol 1995; 120 (4): 423-32
6. 6. Schuman JS. Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension. Surv Ophthalmol 1996; 41 Suppl. I: S127-37
7. 7. Strahlman E, Tipping R, Vogel R, et al. A double-masked, randomized 1-year study comparing dorzolamide (trusopt), timolol, and betaxolol. Arch Ophthalmol 1995; 113 (8); 1009-16
8. t™), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Am J Ophthalmol 1998; 126 (3): 400-8
9. 9. Boyle JE, Ghosh K, Gieser DK, et al. A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide. Ophthalmology 1998; 105 (10); 1945-51
10. 10. Alm A, Stjernschantz J, the Scandinavian Latanoprost Study Group. Effects on intraocular pressure and side-effects of 0.005% latanoprost applied once daily, evening or morning: A comparison with timolol. Ophthalmology 1995; 102 (12); 1743-52
11. 11. Camras CB, the United States Latanoprost Study Group. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month, masked, multi-center trial in the United States. Ophthalmology 1996; 103 (1): 138-47
12. 12. Watson P, Stjernschantz J, the Latanoprost Study Group. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. Ophthalmology 1996; 103 (1): 126-37
13. 13. Mishima HK, Masuda K, Kitazawa Y, et al. A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension: a 12 week study. Arch Ophthalmol 1996; 114 (8): 929-32
14. 14. Alward WLM. Medical management of glaucoma. N Engl J Med 1998; 339 (18): 1298-307
15. 15. Sugrue MF. New approaches to antiglaucoma therapy. J Med Chem 1997; 40 (18): 2793-809
16. 16. Wayman L, Larsson L-I, Maus T, et al. Comparison of dorzolamide and timolol as suppressors of aqueous humor now in humans. Arch Ophthalmol 1997; 115 (11): 1368-71
17. 17. Larsson L-I, Alm A. Aqueous humor flow in human eyes treated with dorzolamide and different doses of acetazolamide. Arch Ophthalmol 1998; 116 (1): 19-24
18. 18. Maus TL, Larsson L-I, McLaren JW, et al. Comparison of dorzolamide and acetazolamide as suppressors of aqueous humor flow in humans. Arch Ophthalmol 1997; 115 (1): 45-9
19. 19. Rosenberg LF, Krupin T, Tang L-Q, et al. Combination of systemic acetazolamide and topical dorzolamide in reducing intraocular pressure and aqueous humor formation. Ophthalmology 1998; 105 (1): 88-93
20. 20. Strahlman E, Tipping R, Vogel R, et al. A six-week dose-response study of the ocular hypotensive effect of dorzolamide with a one-year extension. Am J Ophthalmol 1996; 122 (2): 183-94
21. 21. LeBlanc RP, for the Brimonidine Study Group 2. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Ophthalmology 1998; 105 (10): 1960-7
22. 22. Schuman JS, Horwitz B, Choplin NT, et al. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension: a controlled, randomized, multicenter clinical trial. Arch Ophthalmol 1997; 115 (7): 847-52
23. 23. Camras CB, Wax MB, Ritch R, et al. Latanoprost treatment for glaucoma: effects of treating for 1 year and of switching from timolol. Am J Ophthalmol 1998; 126 (3): 390-9
24. 24. Clineschmidt CM, Williams RD, Snyder E, et al. A randomised Z trial in patients inadequately controlled with timolol alone comparing the dorzolamide-timolol combination to monotherapy with timolol or dorzolamide. Ophthalmology 1998; 105 (10): 1952-9
25. 25. Adamsons I, Clineschmidt C, Polis A, et al. The efficacy and safety of dorzolamide as adjunctive therapy to timolol maleate gellan solution in patients with elevated intraocular pressure. J Glaucoma 1998; 7 (4): 253-60
26. 26. Strahlman ER, Vogel R. Tipping R, et al. The use of dorzolamide and pilocarpine as adjunctive therapy to timolol in patients with elevated intraocular pressure. Ophthalmology 1996; 103 (8): 1283-93
27. 27. Laibovitz R, Strahlman ER, Barber BL, et al. Comparison of quality of life and patient preference of dorzolamide and pilocarpine as adjunctive therapy to timolol in the treatment of glaucoma. J Glaucoma 1995; 4 (5): 306-13
28. 28. Mehta NH, Simmons ST, Alphagan/Trusopt Study Group. The safety and efficacy of brimonidine and dorzolamide as concomitant therapy in primary open angle glaucoma and ocular hypertension [abstract]. Invest Ophthalmol Vis Sci 1998; 39 (4): S481
29. 29. Alm A, Widengard I, Kjellgren D, et al. Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol. Br J Ophthalmol 1995; 79 (1): 12-6
30. 2α analogue, and timolol in patients with elevated intraocular pressure. Br J Ophthalmol 1994; 78 (12): 899-902
31. 31. Diestelhorst M, Almegard B. Comparison of two fixed combinations of latanoprost and timolol in open-angle glaucoma. Graefes Arch Clin Exp Ophthalmol 1998; 236: 577-81
32. 32. Emmerich KH. A comparison of latanoprost monotherapy to dorzolamide combined with timolol in glaucoma and ocular hypertension patients. American Academy of Ophthalmology Final Program; 1998 Nov 8-11; New Orleans, 137
33. 33. Ciappetta R, Frezzotti P, Nuti A et al. Additivity of latanoprost and pilocarpine to timolol in POAG patienls [abstract]. Invest Ophthalmol Vis Sci 1998; 39 (4): S256
34. 34. Stewart R, the Brinzolamide Comfort Study Group. The ocular comfort of tid-dosed brinzolamide 1.0% compared to tiddosed dorzolamide 2.0% in patients with primary open-angle glaucoma or ocular hypertension [abstract]. Invest Ophthalmol Vis Sci 1997; 38 (4): S559
35. 35. Lass JH, Khosrof SA, Laurence JH, et al. A double-masked, randomised, 1-year study comparing the corneal effects of dorzolamide, timolol, and betaxolol. Arch Ophthalmol 1998; 116 (8): 1003-10
36. 36. Wilkerson M, Cyrlin M, Lippa EA, et al. Hour-week safety and efficacy study of dorzolamide, a novel, active topical carbonic anhydrase inhibitor. Arch Ophthalmol 1993, 111 (10): 1343-50
37. 37. Uva MG, Longo A, Ott JP, et al. 2% Dorzolamide and cornea: an ultrabiomicroscopic study [abstract]. Invest Ophthalmol Vis Sci 1998; 39 (4): S708
38. 38. Egan CA, Hodge DO, McLaren JW, et al. Effect of dorzolamide on corneal endothelial function in normal human eyes. Invest Ophthalmol Vis Sci 1998; 39 (1): 23-9
39. 39. Konowal A, Morrison JC, Brown SVL, et al. Irreversible corneal decompensation in patients treated with topical dorzolamide. Am J Ophthalmol 1999; 127: 403-6
40. 40. Herndon LW, Choudhri SA, Cox T, et al. Central corneal thickness in normal, glaucomatous, and ocular hypertensive eyes. Arch Ophthalmol 1997; 115 (9): 1137-41
41. 41. Wand M. Latanoprost and hyperpigmentation of eyelashes. Arch Ophthalmol 1997; 115 (9): 1206-8
42. 42. Johnstone MA. Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost. Am J Ophthalmol 1997; 124 (4): 544-7
43. 43. Watson PG, the Latanoprost Study Group. Latanoprost: two years' experience of its use in the United Kingdom. Ophthalmology 1998; 105 (1): 82-7
44. 44. Albert DM, Green WR, Grossniklaus HE et al. Histopathological finding in iris specimens from patients with glaucoma treated with latanoprost. American Academy of Ophthalmology Final Program; 1998 Nov 8-11 ; New Orleans, 153
45. 45. Zhan G-L, Toris CB, Camras CB, et al. Prostaglandin-induced iris color darkening: an experimental model. Arch Ophthalmol 1998; 116 (8): 1065-8
46. 46. Zhan G-L, Ohia SE, Camras CB, et al. Superior cervical ganglionectomy-induced lowering of intraocular pressure in rabbits: role of prostaglandins and neuropeptide Y. Gen Pharmacol 1999; 32: 189-94
47. 47. Rowe JA, Hattenhauer MG, Herman DC. Adverse side effects associated with latanoprost. Am J Ophthalmol 1997; 124 (5): 683-5
48. 48. Avakian A, Renier SA, Butler PJ. Adverse effects of latanoprost on patients with medically resistant glaucoma. Arch Ophthalmol 1998; 116 (5): 679-80
49. 49. Warwar RE, Bullock JD, Ballal D. Cystoid macular edema and anterior uveitis associated with latanoprost use: experience and incidence in a retrospective review Ophthalmology 1998; 105 (2): 263-8
50. 50. Gaddie IB, Bennett DW. Cystoid macular edema associated with the use of latanoprost. J Am Optom Assoc 1998; 69 (2): 122-8
51. 51. Heier JS, Steinert RF, Frederick AR. Cystoid macular edema associated with latanoprost use. Arch Ophthalmol 1998; 116 (5): 680-2
52. 52. Callanan D, Fellman RL, Savage JA. Latanoprost-associated cystoid macular edema. Am J Ophthalmol 1998; 126 (1): 134-5
53. 53. Ayyala RS, Cruz DA, Margo CE, et al. Cystoid macular edema associated with latanoprost in aphakic and pseudophakic eyes. Am J Ophthalmol 1998; 126 (4): 602-4
54. 54. Fechtner RD, Khouri AS, Zimmerman TJ, et al. Anterior uveitis associated with latanoprost. Am J Ophthalmol 1998; 126 (1): 37-41
55. 55. Camras CB. CME and anterior uveitis with latanoprost use [letter]. Ophthalmology 1998; 105 (11): 1978-81
56. 56. Schumer RA, Camras CB, Mandahl A. Occurrence of cystoid macular edema in eyes treated with latanoprost: preliminary analysis. In: Krieglstein GK, editor. Glaucoma update VI. Heidelberg: Springer-Verlag. In press
57. 57. Eisenberg DL. CMC and anterior uveitis with latanoprost use [letter]. Ophthalmology 1998; 105 (11): 1978-81
58. 58. Thorne JE, Maguire AM, Lanciano R. CME and anterior uveitis with latanoprost use [letter]. Ophthalmology 1998; 105 (11): 1981-3
59. 59. Carlsen J, Durcan J, Zabriskie N, et al. Nephrolithiasis with dorzolamide. Arch Ophthalmol 1999; 117: 1087-8
60. 60. Biollaz J, Munafo A, Buclin T, et al. Whole-blood pharmacokinetics and metabolic effects of the topical carbonic anhydrase inhibitor dorzolamide. Eur J Clin Pharmacol 1995; 47: 455-60
61. 61. Hodapp E, Kolker AE, Kass MA, et al. The effect of topical clonidine on intraocular pressure. Arch Ophthalmol 1981; 99 (7): 1208-11
62. 62. Coleman AL, Robin AL, Pollack IP, et al. Cardiovascular and intraocular pressure effects and plasma concentrations of apraclonidine. Arch Ophthalmol 1990; 108 (9): 1264-7
63. 63. Nordlund JR, Pasquale LR, Robin AL, et al. The cardiovascular, pulmonary, and ocular hypotensive effects of 0.2% brimonidine. Arch Ophthalmol 1995; 113 (1): 77-83
64. 64. Derick RJ, Robin AL, Walters TR, et al. Brimonidine tartrate: a one-month dose response study. Ophthalmology 1997; 104 (1): 131-6
65. 65. Carlsen JO, Norman BS, Zabriskie A, et al. Apparent central nervous system depression in infants after the use of topical brimonidine. Am J Ophthalmol 1999; 128: 255-6
66. 2α analogue. In: Samuelsson B, Ramwell PW, Paoletti R, et al, editors. Advances in prostaglandin, thromboxane, and leukotriene research. New York; Raven Press, Ltd, 1995: 513-8
67. 67. Hedner J, Svedmyr N, Lunde H, et al. The lack of respiratory effects of the ocular hypotensive drug latanoprost in patients with moderate-steroid treated asthma. Surv Ophthalmol 1997; 41 Suppl. 2: S111-5
68. 68. Alcon Ophthalmic. Azopt™ (brinzolamide ophthalmic suspension) 1%: prescribing information. Fort Worth (TX): Alcon Laboratories Inc., 1998
69. 69. Merck & Co., Inc. Trusopt® (dorzolamide hydrochloride ophthalmic solution): prescribing information. West Point (PA): Merck & Co., Inc., 1998
70. 70. Derick RJ, Robin AL, Tielsch J, et al. Once-daily versus twice-daily levobunolol (0.5%) therapy: a crossover study. Ophthalmology 1992, 99 (3): 424-9
71. 71. Novack GD. Ophthalmic beta-blockers since timolol. Surv Ophthalmol 1987; 31 (5): 307-27
72. 72. Stewart WC, Leland TM, Cate EA, et al. Efficacy and safety of timolol solution once daily versus timolol gel in treating elevated intraocular pressure. J Glaucoma 1998; 7 (6): 402-7
73. 73. Rakofsky SI, Melamed S, Cohen JS, et al. A comparison of the ocular hypotensive efficacy of once-daily and twice-daily levobunolol treatment. Ophthalmology 1989; 96 (1): 8-11
74. 74. Nagasubramanian S, Sheth GP, Hitchings RA, et al. Intraocular pressure-reducing effect of PhXA41 in ocular hypertension: comparison of dose regimens. Ophthalmology 1993; 100 (9): 1305-11
75. 75. Lindén C, Alm A. Latanoprost twice daily is less effective than once daily: indication of receptor subsensitivity? Curr Eye Res 1998; 17 (6): 567-72
76. 76. Lindén C, Nuija E, Alm A. Effects on IOP restoration and blood-aqueous barrier after long term treatment with latanoprost in open angle glaucoma and ocular hypertension. Br J Ophthalmol 1997; 81 (5): 370-2
77. 77. Schlecht LP, Brubaker RF. The effects of withdrawal of timolol in chronically treated glaucoma patients. Ophthalmology 1988; 95 (9): 1212-6
78. 78. Cramer JA, Mattson RH, Prevey ML, et al. How often is medication taken as prescribed? A novel assessment technique. JAMA 1989; 261 (22): 3273-7
79. 79. Kolker AE, Becker B. Epinephrine maculopathy. Arch Ophthalmol 1968; 79 (5): 552-62
80. 80. Michels RG, Maumenee AE. Cystoid macular edema associated with topically applied epinephrine in aphakic eyes. Am J Ophthalmol 1975; 80 (3 Pt I): 379-88
81. 81. Thomas JV, Gragoudas ES, Blair NP, et al. Correlation of epinephrine use and macular edema in aphakic glaucomatous eyes. Arch Ophthalmol 1978; 96 (4): 625-8
82. 82. Diggory P, Heyworth P, Chau G, et al. Improved lung function tests on changing from topical timolol: non-selective beta-blockade impairs lung function tests in elderly patients. Eye 1993; 7 Pt 5; 661-3